8IN Stock Overview
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Syneos Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.00 |
| 52 Week High | US$51.08 |
| 52 Week Low | US$25.67 |
| Beta | 1.58 |
| 1 Month Change | 3.63% |
| 3 Month Change | 3.63% |
| 1 Year Change | -17.96% |
| 3 Year Change | -14.53% |
| 5 Year Change | -7.26% |
| Change since IPO | 37.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8IN | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 1.5% | -2.4% | -1.7% |
| 1Y | -18.0% | -8.7% | 1.4% |
Return vs Industry: 8IN exceeded the German Life Sciences industry which returned -22.5% over the past year.
Return vs Market: 8IN underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 8IN volatility | |
|---|---|
| 8IN Average Weekly Movement | 1.8% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8IN has not had significant price volatility in the past 3 months.
Volatility Over Time: 8IN's weekly volatility has decreased from 8% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 28,768 | Michelle Keefe | www.syneoshealth.com |
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
Syneos Health, Inc. Fundamentals Summary
| 8IN fundamental statistics | |
|---|---|
| Market cap | €4.22b |
| Earnings (TTM) | €67.43m |
| Revenue (TTM) | €5.13b |
62.6x
P/E Ratio0.8x
P/S RatioIs 8IN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8IN income statement (TTM) | |
|---|---|
| Revenue | US$5.42b |
| Cost of Revenue | US$4.22b |
| Gross Profit | US$1.20b |
| Other Expenses | US$1.13b |
| Earnings | US$71.22m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 22.14% |
| Net Profit Margin | 1.31% |
| Debt/Equity Ratio | 75.8% |
How did 8IN perform over the long term?
See historical performance and comparison